Immunization News and Research

RSS

New testing protocol for SARS-CoV-2 can process thousands of samples within 48 hours

Researchers at the Vienna BioCenter designed a testing protocol for SARS-CoV-2 that can process tens of thousands of samples in less than 48 hours. The method, called SARSeq, is published in the journal Nature Communications and could be adapted to many more pathogens.

25 May 2021

Do vaccinations result in anti-SARS-CoV-2 antibodies in human milk?

The aim of this study investigates the impact of different types of vaccines on the anti-SARS-CoV-2 Immunoglobulin A (IgA) and Immunoglobulin G (IgG) antibody levels found in human milk.

25 May 2021

Heterologous prime-boost immunization with AstraZeneca and Pfizer COVID-19 vaccines safe and well-tolerated, study finds

A team of scientists from Germany has recently evaluated the reactogenicity profile of heterologous ChAdOx1 nCoV-19/BNT162b2 prime-boost vaccination among healthcare workers. The findings reveal that a 12-week interval regimen of heterologous vaccination is well-tolerated among participants. The study is currently available on the medRxiv* preprint server.

25 May 2021

Researchers identify aluminum hydroxide/TLR9 agonist as potential adjuvant to improve RBD-based COVID-19 vaccine efficacy

The study findings reveal that RBD-based vaccines adjuvanted with the formulation can induce strong anti-SARS-CoV-2 neutralizing immunity in young and aged mice. The study is currently available on the bioRxiv* preprint server.

24 May 2021

Australian discovery could speed up SARS-CoV-2 vaccine development

To address this gap, researchers from Australia recently examined the relationship between levels of in vitro neutralization and the observed protection obtained from SARS-CoV-2 infection. They used data from 7 currently available vaccines and convalescent cohorts. Their research is published in the journal Nature Medicine.

22 May 2021

Despite frequent vaccinations, COVID-19 could continue to cause recurrent waves and deaths

Covid-19 could continue to cause recurrent waves and deaths despite frequent vaccinations according to a new study from the University of East Anglia.

21 May 2021

Pfizer-BioNTech and Sinovac vaccines boost SARS-CoV-2 neutralizing responses

Researchers in the United States and Chile have provided preliminary evidence that individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – mount a robust neutralizing antibody response against the virus that can be significantly boosted by two doses of Sinovac Biotech’s CoronaVac vaccine or one dose of Pfizer-BioNTech’s BNT162b2 vaccine.

21 May 2021

Resuming global childhood vaccination campaigns during the COVID-19 pandemic

New research published on the medRxiv* preprint server suggests childhood vaccination to prevent other infectious diseases has plummeted during the pandemic. The decrease appears to stem from the suspension of health campaigns promoting immunization and the risk of catching the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).

20 May 2021

World Health Assembly highlights the urgency to end COVID-19 pandemic and prevent the next one

In a year when COVID-19 threatens the health and well-being of everyone on the planet, the seventy-fourth session of the World Health Assembly (WHA) will stress the urgency of ending the current pandemic and preventing the next one by building a healthier, safer and fairer world.

20 May 2021

Plant-produced COVID-19 vaccine shows potent immunogenic profile in humans

An interim report on a phase 2 clinical trial indicates both the safety and efficacy of a plant-produced virus-like particle vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vaccine candidate has shown an acceptable safety profile and high potency in inducing humoral and cellular immune responses in adults (18 – 64 years) and elderly (65 years and above) individuals. The report is currently available on the medRxiv* preprint server.

20 May 2021

Childhood immunization rates in Texas declined sharply during COVID-19 pandemic

Despite expert recommendations that children continue to get regularly scheduled vaccines during the pandemic, vaccination rates have decreased in several states.

20 May 2021

Protein-based vaccines against SARS-CoV-2 may provide advantages over mRNA-based vaccines

Researchers in the UK have developed a protein-based subunit vaccine directed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could serve as an alternative to the mRNA-based vaccines currently approved for protecting against coronavirus disease 2019 (COVID-19).

20 May 2021

Pfizer/BioNTech COVID-19 vaccine induces a stronger antibody response when given at an extended interval

Scientists have recently investigated the dynamics of immune responses in elderly people who have received two doses of the Pfizer/BioNTech COVID-19 vaccine.

19 May 2021

Sequentia collaborated with Nextbiomics to obtain a novel immunization model against COVID-19

Sequentia Biotech and NextBiomics announced the filing of a patent application for a bacterial vaccine against the COVID-19 syndrome.

From Sequentia Biotech 19 May 2021

Antibody response following SARS-CoV-2 mRNA vaccine is greater than natural infection

Researchers in the United States have provided the first evidence that messenger RNA (mRNA)-based vaccines against severe acute respiratory coronavirus 2 (SARS-CoV-2) induce a broader array of antibody subtypes against the viral spike protein than natural infection does.

19 May 2021

Methotrexate impairs immunogenicity of BNT162b2 SARS-CoV-2 vaccine in patients with immune-mediated inflammatory diseases

Researchers from Germany and the USA recently investigated the cellular and humoral immune responses of patients with IMIDs on immunomodulatory treatment to mRNA COVID-19 vaccines. The research is published on the medRxiv* preprint server.

19 May 2021

SARS-CoV-2 mRNA vaccine PTX-COVID19-B safe and highly immunogenic in preclinical study

COVID-19, the coronavirus disease of 2019, is one of the worst pandemics in human history. It emerged in December 2019 and is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Nearly 164 million SARS-CoV-2 infections and 3.4 million deaths have been reported globally since the beginning of the pandemic, which is still raging in many countries.

18 May 2021

Enhanced version of CureVac’s COVID-19 vaccine could help address supply shortages

Researchers in Germany have demonstrated the preclinical effectiveness of a next-generation coronavirus disease 2019 (COVID-19) vaccine at enhancing antibody responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

16 May 2021

What does approval of the Pfizer vaccine for teens and preteens mean for my child?

Extending the emergency use of the Pfizer-BioNTech vaccine to preteens and young adolescents adds nearly 17 million more Americans to the pool of those eligible to be immunized against covid-19, helping to build a vaccinated population closer to herd immunity. Moderna and Johnson & Johnson are also testing the efficacy of their vaccines in teens and children.

14 May 2021

A SARS-CoV-2 ferritin nanoparticle vaccine elicits broad immunity

In a recent bioRxiv* preprint research paper, M. Gordon Joyce et al. designed engineered nanoparticle immunogens that recapitulate the structural and antigenic properties of prefusion Spike (S), S1 and receptor-binding domain (RBD). They demonstrated that these immunogens induced robust S-binding, ACE2 (angiotensin-converting enzyme)-inhibition, and authentic and pseudovirus neutralizing antibodies against SARS-CoV-2 in mice.

13 May 2021

Immunization News and Research

New testing protocol for SARS-CoV-2 can process thousands of samples within 48 hours

Do vaccinations result in anti-SARS-CoV-2 antibodies in human milk?

Heterologous prime-boost immunization with AstraZeneca and Pfizer COVID-19 vaccines safe and well-tolerated, study finds

Researchers identify aluminum hydroxide/TLR9 agonist as potential adjuvant to improve RBD-based COVID-19 vaccine efficacy

Australian discovery could speed up SARS-CoV-2 vaccine development

Despite frequent vaccinations, COVID-19 could continue to cause recurrent waves and deaths

Pfizer-BioNTech and Sinovac vaccines boost SARS-CoV-2 neutralizing responses

Resuming global childhood vaccination campaigns during the COVID-19 pandemic

World Health Assembly highlights the urgency to end COVID-19 pandemic and prevent the next one

Plant-produced COVID-19 vaccine shows potent immunogenic profile in humans

Childhood immunization rates in Texas declined sharply during COVID-19 pandemic

Protein-based vaccines against SARS-CoV-2 may provide advantages over mRNA-based vaccines

Pfizer/BioNTech COVID-19 vaccine induces a stronger antibody response when given at an extended interval

Sequentia collaborated with Nextbiomics to obtain a novel immunization model against COVID-19

Antibody response following SARS-CoV-2 mRNA vaccine is greater than natural infection

Methotrexate impairs immunogenicity of BNT162b2 SARS-CoV-2 vaccine in patients with immune-mediated inflammatory diseases

SARS-CoV-2 mRNA vaccine PTX-COVID19-B safe and highly immunogenic in preclinical study

Enhanced version of CureVac’s COVID-19 vaccine could help address supply shortages

What does approval of the Pfizer vaccine for teens and preteens mean for my child?

A SARS-CoV-2 ferritin nanoparticle vaccine elicits broad immunity

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News